澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

PARADIGM BIOPHARMACEUTICALS

0.245

0.000

成交量：- -

成交额：- -

市值：1.49亿

市盈率：-1.61

高：0.245

开：0.245

低：0.245

收：0.245

52周最高：0.470

52周最低：0.135

股本：6.07亿

流通股本：3.53亿

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.152

每股收益(LYR):-0.152

净资产收益率：-456.96%

总资产收益率：-138.75%

市净率：42.84

市盈率(LYR):-1.61

数据加载中...

总览公司新闻资讯公告

概念

医药生物股+0.66%

资金流向

资金流入：

资金流出：

新闻资讯

Paradigm Biopharmaceuticals临床审查及重组进程预计至少耗时八周

Paradigm Biopharmaceuticals停牌待公布三期临床试验中期分析结果

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/PAR.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PAR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","market":"AU","secType":"STK","nameCN":"PARADIGM BIOPHARMACEUTICALS","latestPrice":0.245,"timestamp":1791781920000,"preClose":0.245,"halted":0,"volume":0,"delay":0,"changeRate":0,"nameEN":"PARADIGM BIOPHARMACEUTICALS","floatShares":353065639,"shares":606848701,"eps":-0.152232,"marketStatus":"未开盘","change":0,"latestTime":"10-12 16:12:00 AEDT","open":0.245,"high":0.245,"low":0.245,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.152232,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791846000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.245,"openAndCloseTimeList":[[1791759600000,1791781200000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"PAR.AU","preClose":0.245,"auctionPrice":0.255,"auctionVolume":69,"auction":1,"marketStatus":"盘前竞价","timestamp":1790118118758}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"PAR.AU\",,,,,undefined,":{"symbol":"PAR.AU","floatShares":353065639,"roa":"-138.75%","roe":"-456.96%","lyrEps":-0.152232,"shares":606848701,"dividePrice":0,"high":0.245,"amplitude":0,"preClose":0.245,"low":0.245,"week52Low":0.135,"pbRate":"42.84","psRate":"17595.02","week52High":0.47,"institutionHeld":0,"latestPrice":0.245,"eps":-0.152232,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.152232,"open":0.245,"prevYearClose":0.34,"prevWeekClose":0.245,"prevMonthClose":0.245,"prevQuarterClose":0.245,"fiveDayClose":0.245,"twentyDayClose":0.24,"sixtyDayClose":0.165,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PAR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-02-06","symbol":"PAR.AU","defaultRemindTime":1738796400000,"type":"split","dateTimestamp":1738760400000,"forFactor":4,"toFactor":5,"ratio":0.8},{"market":"AU","date":"2022-08-17","symbol":"PAR.AU","defaultRemindTime":1660694400000,"type":"split","dateTimestamp":1660658400000,"forFactor":992772,"toFactor":1000000,"ratio":0.992772}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PAR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PAR.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1133244650","title":"Paradigm Biopharmaceuticals临床审查及重组进程预计至少耗时八周","url":"https://stock-news.laohu8.com/highlight/detail?id=1133244650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133244650?lang=zh_cn&edition=fundamental","pubTime":"2026-09-30 07:49","pubTimestamp":1790725749,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals临床审查及重组进程预计至少耗时八周","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145323734","title":"Paradigm Biopharmaceuticals停牌待公布三期临床试验中期分析结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145323734","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145323734?lang=zh_cn&edition=fundamental","pubTime":"2026-09-21 06:49","pubTimestamp":1789944550,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals——这家生物制药公司已宣布停牌，静候其三期临床试验的中期分析数据出炉。此番停牌举措，无疑为市场投下了一枚悬念十足的重磅炸弹。眼下，投资者们正屏息凝神，翘首以盼这项关键性研究的最新进展。毕竟，中期分析结果往往能为药物的有效性和安全性提供早期信号，其重要性不言而喻。停牌期间，交易活动暂时中止，一切悬念都将留待结果正式揭晓之时。如今，Paradigm Biopharmaceuticals正处于这一关键时刻，市场各方均在密切注视。一切谜底，静待揭晓。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAR.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/PAR.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"医药生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.006583}]}}